A comprehensive overview of eco-friendly bio-fertilizers extracted from living organisms.

Currently, sustainable agriculture involves ecofriendly techniques, which include biofertilization. Biofertilizers increase plant productivity by improving soil fertility and nutrient content. A wide range of living organisms can be applied as biofertilizers and increase soil fertility without causing pollution due to their biodegradability. The organisms can be microorganisms like bacteria, microalgae, and micro fungi or macro organisms like macroalgae, macro fungi, and higher plants. Biofertilizers extracted from living organisms or their residues will be increasingly used rather than chemical fertilizers, which cause heavy metal accumulation in soil. Biofertilizer use aims for sustainable development in agriculture by maintaining the soil. This will mitigate climate change and related impacts and will also lower many serious diseases resulting from pollution such as cancer, liver and renal failure, and immune diseases. This review is a comprehensive overview of biofertilizers extracted from a range of living organisms from the Kingdoms Monera to Plantae and included bacteria, algae, fungi, and higher plants. Organisms that play a vital role in elevating soil nutrients in a safe, cheap, and ecofriendly manner are included in the review to promote their potential commercial application.

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity.

Lung cancer is the second most commonly diagnosed cancer in the world. In terms of the diagnosis of lung cancer, combination carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125) detection had higher sensitivity, specificity, and diagnostic odds ratios than CEA detection alone. Most individuals with elevated serum CA125 levels had lung cancer that was either in stage 3 or stage 4. Serum CA125 levels were similarly elevated in lung cancer patients who also had pleural effusions or ascites. Furthermore, there is strong evidence that human lung cancer produces CA125 in vitro, which suggests that other clinical illnesses outside of ovarian cancer could also be responsible for the rise of CA125. MUC16 (CA125) is a natural killer cell inhibitor. As a screening test for lung and ovarian cancer diagnosis and prognosis in the early stages, CA125 has been widely used as a marker in three different clinical settings. MUC16 mRNA levels in lung cancer are increased regardless of gender. As well, increased expression of mutated MUC16 enhances lung cancer cells proliferation and growth. Additionally, the CA125 serum level is thought to be a key indicator for lung cancer metastasis to the liver. Further, CA125 could be a useful biomarker in other cancer types diagnoses like ovarian, breast, and pancreatic cancers. One of the important limitations of CA125 as a first step in such a screening technique is that up to 20% of ovarian tumors lack antigen expression. Each of the 10 possible serum markers was expressed in 29-100% of ovarian tumors with minimal or no CA125 expression. Therefore, there is a controversy regarding CA125 in the diagnosis and prognosis of lung cancer and other cancer types. In this state, preclinical and clinical studies are warranted to elucidate the clinical benefit of CA125 in the diagnosis and prognosis of lung cancer.

Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Blockers of the renin-angiotensin system are effective in the treatment of experimental and clinical diabetic nephropathy. An approach different from blocking the formation or action of angiotensin II (1-8) that could also be effective involves fostering its degradation. Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase that cleaves angiotensin II (1-8) to form angiotensin (1-7). Therefore, we examined the renal effects of murine recombinant ACE2 in mice with streptozotocin-induced diabetic nephropathy as well as that of amplification of circulating ACE2 using minicircle DNA delivery prior to induction of experimental diabetes. This delivery resulted in a long-term sustained and profound increase in serum ACE2 activity and enhanced ability to metabolize an acute angiotensin II (1-8) load. In mice with streptozotocin-induced diabetes pretreated with minicircle ACE2, ACE2 protein in plasma increased markedly and this was associated with a more than 100-fold increase in serum ACE2 activity. However, minicircle ACE2 did not result in changes in urinary ACE2 activity as compared to untreated diabetic mice. In both diabetic groups, glomerular filtration rate increased significantly and to the same extent as compared to non-diabetic controls. Albuminuria, glomerular mesangial expansion, glomerular cellularity, and glomerular size were all increased to a similar extent in minicircle ACE2-treated and untreated diabetic mice, as compared to non-diabetic controls. Recombinant mouse ACE2 given for 4 weeks by intraperitoneal daily injections in mice with streptozotocin-induced diabetic nephropathy also failed to improve albuminuria or kidney pathology. Thus, a profound augmentation of ACE2 confined to the circulation failed to ameliorate the glomerular lesions and hyperfiltration characteristic of early diabetic nephropathy. These findings emphasize the importance of targeting the kidney rather than the circulatory renin angiotensin system to combat diabetic nephropathy.

Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood.

Apparent mineralocorticoid excess syndrome (AME) is an autosomal recessive genetic disorder caused by a deficiency in the enzyme 11ß-hydroxysteroid dehydrogenase type 2 (11ß-HSD). We report a 36-year-old male who was hypertensive from birth and was diagnosed with AME at 8 years of age. There was continuous documentation of his hypertension and hypokalemic alkalosis throughout childhood, during which spironolactone and supplemental potassium were administered. At 33 years of age, the patient received a renal transplant, and following this the AME appears to have been cured clinically with remission of his low renin hypertension and hypokalemic alkalosis despite termination of treatment with spironolactone and potassium supplements.

Sevoflurane-emergence agitation: effect of supplementary low-dose oral ketamine premedication in preschool children undergoing dental surgery.

BACKGROUND AND OBJECTIVE: The use of sevoflurane in paediatric anaesthesia which could enable rapid recovery is complicated by the frequent occurrence of emergence agitation. The aim of this study was to test the efficacy of supplementing midazolam-based oral premedication with low-dose oral ketamine in reducing sevoflurane-related emergence agitation. METHODS: Ninety-two healthy preschool children who have been scheduled for elective dental procedures under general anaesthesia were allocated into two groups (46 patients for each): group M received oral midazolam 0.5 mg kg(-1), whereas group KM received similar premedication in addition to ketamine 2 mg kg(-1). Acceptance of drug mixture and onset of action were monitored over the next 30 min. Induction of anaesthesia was carried out using sevoflurane 8 vol% in 100% oxygen via face mask. Anaesthesia was maintained with sevoflurane 1.5-2 vol% in oxygen-nitrous oxide mixture. Following extubation, standard scoring scale was used for assessing quality of emergence. Agitation parameters were measured using a five-point scale. Agitated children were managed by giving intravenous increments of fentanyl 1 microg kg(-1). The time of hospital discharge allowance was recorded. RESULTS: Vast majority of children accepted the premedication. There were no significant differences between both groups regarding recovery from sevoflurane and allowance of hospital discharge. Onset of action of premedication was shorter in group KM. Similarly, postoperative agitation score and rescue fentanyl consumption were markedly lower in group KM upon admission to the postanaesthesia care unit (P<0.01). CONCLUSION: Adding a low dose of oral ketamine to midazolam-based oral premedication in preschool children undergoing dental surgery reduced emergence agitation without delaying hospital discharge.